DTC Spending During Rx Life Yields OTC Switch Market Share
This article was originally published in The Pink Sheet Daily
To fully capitalize on potential sales, Rx-to-OTC switch sponsors must plan marketing strategies years before a switch is proposed and continue for years after launch, IRI data show. Other factors include working with managed care, product differentiation, pricing and consumer satisfaction.
You may also be interested in...
Novartis plans to prioritize converting patients currently treated with prescription Prevacid when the proton pump inhibitor becomes available over-the-counter, rather than winning over Prilosec OTC users, a Novartis executive said
Sales of Johnson & Johnson's allergy drug Zyrtec show managed care organizations learned from previous switches and used a "softer" approach to steer clients away from Rx drugs to an OTC product, according to market analysts
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.